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ABSTRACT 
Objective: The objective of our study was to evaluate a possible relation between the 
volume of atypical meningiomas (AMs) and the risk of tumour recurrence, as well as 
progression-free survival (PFS). 
Material and methods: We evaluated 81 patients diagnosed with AMs (WHO grade 
II meningioma) who have undergone surgery at the "Prof. Dr. N. Oblu" Emergency 
Clinical Hospital Iasi between January 1, 2010, and December 31, 2019. The recorded 
data were demographic and imagistic (MRI, contrast-enhanced T1WI). We calculated 
the tumour volume prior to the surgery and evaluated the tumour recurrence using 
MRI at 12, 24, 36, 48 and 60 months after the surgery. 
Results: 50.6% of patients had meningioma volume < 26.4 cm3. Women had larger 
tumour volumes than men (52.6%). Patients of age ≤ 60 years old, had tumour 
volumes ˃ 26.4 cm3 in 58.5% of cases and meningiomas with volumes ˃ 26.4 cm3 
recurred earlier (p=0.010). Also, patients who had tumour volumes ˃ 26.4 cm3, had a 
shorter PFS (40.976 months), compared to patients with tumour volumes < 26.4 cm3, 
who had better PFS (53.4 months). 
Conclusions: the tumour volume of AMs ˃  26.4 cm3 represents a negative prognostic 
factor for both early tumour recurrence and reduced PFS. 
 
 
INTRODUCTION
Meningiomas are the most common primary intracranial tumors in 
adults and represent about one third of them (26). Out of the 
histopathological grades of meningiomas, AMs (WHO grade II 
meningiomas) represent approximately 20-30% of them (27, 28, 33), 
and their incidence has increased in the last years (10, 33).  
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Regarding the multiple prognostic factors of tumor 
recurrence in case of AMs (8, 12, 13, 27, 30, 31), some 
studies have reported that the size and volume of the 
tumor would also represent a prognostic factor (16, 
17, 22). Thus, some authors have proved that larger 
size of AMs (for example, over 4.5 cm) are associated 
with early tumor recurrence (16). Other authors have 
reached the conclusion that the size of the 
meningioma is not only a prognostic factor of tumor 
recurrence, but also of the survival of patients, both 
in the case of AMs, as well as in the case of anaplastic 
meningiomas (17). 
 This study is aimed to evaluate the influence of 
the tumor volume on early tumor recurrence, as well 
as on the survival period up to the tumor recurrence. 
 
MATERIAL AND METHODS 
We evaluated the tumor volume of 81 patients 
diagnosed with atypical meningioma (AM), who had 
undergone surgery at the Neurosurgery 
Department, "Prof. Dr. N. Oblu" Emergency Clinical 
Hospital Iasi, followed between January 1, 2010 and 
December 31, 2019. Each patient had the following 
recorded: demographic data regarding age and sex, 
and imaging studies (MRI). The tumor volume was 
calculated using the formula: volume = π /6 x legnth 
x wirdth x height (5, 18, 21, 29), and was analysed on 
magnetic resonance images prior to the surgery 
(contrast-enhanced T1WI). The mean tumor volume 
calculated was of 26.4 cm3, and depending on it, 
patients were grouped into two samples: (1) patients 
whose volume was < 24 cm3 and (2) patients whose 
volume was ˃ 26.4 cm3. We also performed a 
qualitative evaluation of the AMs volume and 
evaluated the relation between the tumor volume, 
the rate of recurrence and PFS. The patients had an 
annual imaging examination (MRI), for a period of 5 
years, and the tumor reccurence/tumor progression 
was defined as any contrast-enhancement at the 
level of the remaining tumor bed, or the increase in 
size of the the remnant tumor. In the cases of 
subtotal tumor resections, we named and classified 
the tumor progression as a tumor recurrence. 
Depending on its location in the intracranian space, 
the meningiomas were classified as: (1) skull base 
meningiomas, (2), convexity meningiomas, (3) 
parasagittal/falcine meningiomas, (4) posterior fossa 
meningiomas, and (5) intraventricular meningiomas. 
In the group of skull base meningiomas were 
included only those located at the level of the 
anterior and middle fossa. Posterior fossa 
meningiomas included all infratentorial 
meningiomas, including tentorium meningiomas or 
those located on the cerebellopontine angle or the 
petroclival junction. The statistical data processing 
was made in SPSS 24.0 (SPSS Inc., Chicago, IL). The 
data were characterized through descriptive 
statistics and frequency distributions. The data 
normality was checked using the Kolmogorov-
Smironov fitting test; after this, we used t-Student 
and ANOVA tests to compare the samples of 
normally distributed data and Mann-Whitney and 
Kruskal-Wallis tests to compare the other samples. 
The qualitative data were characterized through 
frequency distributions and contingency tables, and 
the comparisons were made using the Chi-squared 
test. All p values were 2-tailed; a p value of 0.05 was 
considered significant. The actuarial data were 
represented with Kaplan-Meier plots, and the 
cumulative incidence curves were compared using 
the log-rank test. The study was approved by the 
Reasearch Ethics Committee of the "Grigore T. Popa" 
University of Medicine and Pharmacy of and by the 
Ethical Committee of the "Prof. Dr. N. Oblu" 
Emergency Clinical Hospital of Iași. 
 
RESULTS 
Demography (age, sex) 
The study group included 81 patients, of which most 
cases of AMs were in men, in a percentage of 53.1% 
(n = 43). The age of the patients in the total group 
ranged from 37 to 87 years, with a mean age of 61 
years. When we evaluated the age of patients by sex, 
we noticed that women have a mean age of onset 
younger than men (58.42 years), compared to those 
who have a mean age of disease onset of 63.47 years 
(p=0.0052). 50.6% of patients had ages ≤ 60 years old 
(Figure 1). There were no statistically significant 
differences between the sexes in terms of age 
distribution. All patient characteristics can be seen in 
Table I. 
 
Characteristics  n (%) 
Gender male 
female 
43 (53.1%) 
38 (46.9%) 
Age ≤ 60 years 
˃ 60 years 
41 (50.6%) 
40 (49.4%) 
Tumor localization convexity 
parasagittal/falcine 
skull base 
posterior fossa 
34 (42%) 
21 (25.9%) 
17 (21%) 
6 (7.4%) 
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intraventricular 3 (3.7%) 
Tumor volume < 26.4 cm3 
≥ 26.4 cm3 
41 (50.6%) 
40 (49.4%) 
 
Table I. Characteristics of 81 patients with atypical 
meningiomas. 
 
 
 
Figure 1. Female, 60 years-old with atypical meningioma. A. 
Well-cellularized tumor, infiltrative into adjacent dura mater, 
consisting of meningothelial cells arranged in syncytial pattern, 
with oval nuclei and fine granular chromatin (3 mitoses/10 
high-power fields) (HE, x 400). B and C. two different fields of 
the same tumor showing high expression of Ki-67 LI (mean 
12%) (immunohistochemical staining, x400). 
 
Tumor localization 
Regarding the localization of meningiomas at the 
skull level, most were located on the convexity level 
(42%, n=34), followed by parasagittal/falcine 
localization (25.9%) and at the level of the skull base 
(21%). Smaller percentages were located at the level 
of the posterior fossa (7.4%) or at the intraventricular 
level (3.7%) (Table I).   
Following the qualitative analysis of the tumor 
volume, although there was no statistically 
significant difference between the tumor volume 
and the location of the meningioma at the level of the 
intracranial space, we found, however, that the 
largest tumors were located at the base of the skull, 
with a mean of 53.724 cm3 (ranging between 3.444-
149.094 cm3). These were followed by 
intraventricular meningiomas (mean of 47.927 cm3), 
convexity meningiomas, (mean of 41.396 cm3), 
posterior fossa meningiomas (mean of 39.172 cm3) 
and those with parasagittal/falcine localization 
(mean of 36.596 cm3) (Figure 2). 
 
 
 
Figure 2. The mean tumor volume depending on location 
(personal collection of authors, public domain). 
 
Tumor volume 
The mean tumor volume was 26.4 cm3 and 50.6% of 
patients had meningioma volumes of < 26.4 cm3. 
Analyzing the differences between genres, although 
we did not identify any statistically significant values, 
we found that women had larger meningioma 
volumes than men (52.6%). Also, patients with ages ≤ 
60 years old, had tumor volumes ˃  26.4 cm3 in 58.5% 
of cases.  
 We identified a statistically significant relation 
between the meningioma volume and the tumor 
recurrence (p=0.010). Tumors with volumes ˃ 26.4 
cm3 recurred earlier, and within this group the 
tumor recurrence rate was 17.1% at 12 months, 
19.5% at 24 months and 41.5% at 60 months. On the 
other hand, tumors with volumes < 26.4 cm3 had no 
recurrence in the first 12 months, and the recurrence 
rate at 24 months was 5%. Moreover, 65% (n=26) of 
meningiomas with volumes < 26.4 cm3 had a slow 
recurrence, at 60 months. Also, recurrent 
meningiomas had a larger mean volume (49.438 ± 
41.771) compared to meningiomas that did not recur 
(35.323 ± 35.524). 
 In regards to PFS, we identified a statistically 
significant relation between it and the tumor volume 
(p=0.030). Patients who had tumor volumes ˃ 26.4 
cm3 had shorter PFS (40.976 months). Patients who 
had tumor volumes < 26.4 cm3, had better PFS (53.4 
months) (Figure 3). 
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Figure 3. PFS depending on the tumor volume. It is notable that 
patients with tumor volume < 26.4 cm3 had better PFS. 
 
DISCUSSIONS 
The influence of tumor volume on the tumor 
recurrence risk 
In our study we observed a predominance of 
convexity meningiomas, in agreement with our 
previous studies (9, 11). We also noticed that a higher 
tumor volume has a negative influence on the rate of 
recurrence. Thus, in cases of meningiomas with 
tumor volumes ˃ 26.4 cm3, the recurrence rate was 
higher than in the case of tumors with volumes 
below this value. This correlation between a larger 
size of the meningioma and the existence of the risk 
of tumor recurrence has also been observed by 
other authors in previous studies (16, 17, 19).  
Fernandez et al. reported that the size of over 4.5 
cm of AM is associated with a risk of early recurrence 
(16). Moreover, Garzon-Muvdi et al. also observed in 
his study that the size of the tumor can be 
considered an important factor not only for PFS, but 
also for overall survival. Nakasu et al. also reported 
the mean size of 4.4 ± 1.4 cm to influence tumor 
recurrence compared to non recurrent tumors 
which had a diameter of 3.5 ± 1.5 cm (25). Moreover, 
various authors reported that smaller sized AMs can 
represent a protective factor against tumor 
recurrence (4, 14, 16). 
This relation between the larger tumor volume 
and the risk of tumor recurrence may be explained 
by the fact that a larger size meningioma makes a 
complete tumor resection more difficult due to the 
potential invasion of adjacent structures (3, 15, 20, 
23). 
 Another interesting aspect was observed by 
Magill et al., who proved in a study conducted on 
1113 meningiomas (905 grade I meningiomas and 
208 grade II meningiomas) that the larger the size of 
the tumor, the higher the risks that it would be a 
grade II meningioma (24). In order to explain this, 
Magill et al. considered that there would be two 
possibilities: one would be that the grade II 
meningiomas grow faster than grade I meningiomas, 
and a second that once the slow growth tumor 
reaches a larger size, it develops a microenvironment 
due to hypoxia, which leads to the phenotype of this 
tumor becoming more aggressive (24). 
In recent years, progress has been made in 
establishing the genetic factors that govern the 
growth of meningiomas or leading to their 
transformation into a more malignant histological 
grade, and in this sense, in addition to NF2, 
mutations in SMO, PI3K, TRAF7, KLF4 and AKTI have 
been identified (1, 6, 7). In the case of recurrent 
meningiomas, mutations in POLR2A have also been 
identified (7).  
 
The influence of tumor volume on PFS 
We found that the tumor volume of the meningioma 
influences the survival period until the tumor 
recurrence (p=0.030). Thus, tumor volumes ˃ 26.4 
cm3 had a shorter PFS. This can be explained by the 
fact that larger sized tumors invade more neuro-
vascular structures, which make complete tumor 
resection more difficult, leaving a remnant tumor 
sometimes. In this sense, Wang et al. also found that 
tumors with dimensions ˃ 41.5 mm are associated 
with a higher risk of tumor recurrence (32). Similarly, 
Nakasu et al. 1999 also reported that meningiomas 
with a mean diameter ˃ 44 ± 14 mm have a 
significantly shorter PFS, consistent with other 
authors who consider that the tumor size is 
significantly associated with tumor recurrence in the 
case of patients diagnosed with AMs (2, 14, 17).  
 
CONCLUSIONS 
Our patients’ series demonstrated that the tumor 
volume of AMs ˃ 26.4 cm3 increases the tumor 
recurrence rate and decreases PFS. Moreover, mean 
tumor volumes had bigger values in case of 
recurrent AMs. We consider the tumor volume 
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represents a prognostic factor not only for tumor 
volume, but also for PFS. 
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